



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 166 785 A1

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:

02.01.2002 Bulletin 2002/01

(51) Int Cl.7: A61K 31/415, C07D 231/54,

A61P 7/02, A61P 9/10

(21) Application number: 01113662.9

(22) Date of filing: 19.06.2001

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 19.06.2000 US 212408 P

(71) Applicant: Yung Shin Pharmaceutical Ind. Co., Ltd.  
Taipei, 105 (TW)

(72) Inventors:

- Kuo, Sheng-Chu  
Taichung 404, Taiwan (TW)
- Lee, Fang Yu  
Chung Shan Road Tachi Taichung Taiwan (TW)
- Teng, Che-Ming  
Taipei, Taiwan 106 (TW)

(74) Representative:

Reinhard - Skuhra - Weise & Partner  
Postfach 44 01 51  
80750 München (DE)

## (54) Use of pyrazole derivatives for inhibiting thrombin-induced platelet aggregation

(57) A method of treating a disorder or disease related to thrombin-induced platelet aggregation. The method includes administering to a subject in need thereof a compound having a pyrazolyl core; an aryl

group, via an alkylene linker, bonded to 1-N of the pyrazolyl core; a second aryl group fused at 4-C and 5-C of the pyrazolyl core; and a third aryl group bonded directly to 3-C of the pyrazolyl core.

EP 1 166 785 A1


**Description****Background of the Invention**

5 [0001] Thrombin, an enzyme that cleaves fibrinogen to form fibrin, induces platelet aggregation, which contributes to the pathogenesis of many diseases, e.g., atherosclerosis, myocardial infarction, unstable angina pectoris, and thrombosis. It is therefore desirable to discover a drug which can treat such diseases by specifically inhibiting thrombin-induced platelet aggregation.

**Summary of the Invention**

10 [0002] This invention relates to a method of treating a disorder or disease related to thrombin-induced platelet aggregation. The method includes administering to a subject in need thereof a compound having a pyrazolyl core and three aryl groups: (1) a first aryl group, via an alkylene linker, bonded to 1-N of the pyrazolyl core, (2) a second aryl group fused at 4-C and 5-C of the pyrazolyl core, and (3) a third aryl group bonded directly to 3-C of the pyrazolyl core. Each of these three aryl groups, independently, is phenyl, thienyl, furyl, or pyrrolyl, which is optionally mono-substituted or multi-substituted with halo (e.g., -Cl), alkyl (e.g., -C<sub>5</sub>H<sub>11</sub>), carboxyl, alkoxy carbonyl (e.g., -(C=O)-O-C<sub>5</sub>H<sub>11</sub>), thiocarbonyl (e.g., -(C=O)-S-C<sub>4</sub>H<sub>9</sub>), aminocarbonyl (e.g., -(C=O)-N(C<sub>3</sub>H<sub>7</sub>)<sub>2</sub>), hydroxyalkyl (e.g., -C<sub>6</sub>H<sub>12</sub>OH), alkoxyalkyl (e.g., -C<sub>3</sub>H<sub>6</sub>-O-C<sub>4</sub>H<sub>9</sub>), amino, aminoalkyl (e.g., -C<sub>3</sub>H<sub>6</sub>N(C<sub>3</sub>H<sub>7</sub>)<sub>2</sub>), thioalkyl (e.g., -C<sub>4</sub>H<sub>8</sub>SC<sub>4</sub>H<sub>9</sub>), or oxyalkoxy (e.g., -OCH<sub>2</sub>CH<sub>2</sub>O- as a disubstituent). The compound is administered to the subject in an amount effective for treating the disorder or disease.

15 20 [0003] Below is a formula which encompasses a number of the fused pyrazolyl compounds described above:




40 [0004] Formula (I) includes a pyrazolyl core and three aryl groups, i.e., Ar<sub>1</sub>, Ar<sub>2</sub>, and Ar<sub>3</sub>, as the three aryl groups described above. Each of Ar<sub>1</sub>, Ar<sub>2</sub>, and Ar<sub>3</sub>, independently, is phenyl, thienyl, furyl, or pyrrolyl; each of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub>, independently, is H, halo, -R, -C(=O)OH, -C(=O)OR, -C(=O)SH, -C(=O)SR, -C(=O)NRR', -ROH, -ROR', -RSR', -NRR', -NHR, -RNR'R'', -RNHR', or -RSR', or R<sub>1</sub> and R<sub>2</sub> together, R<sub>3</sub> and R<sub>4</sub> together, or R<sub>5</sub> and R<sub>6</sub> together, are -ORO-, wherein each of R, R', and R'', independently, is C<sub>1-4</sub> alkyl; n is 1, or 2, or 3.

45 [0005] A subset of the compounds of formula (I) are featured by that n is 1, Ar<sub>3</sub> is phenyl, and each of R<sub>5</sub> and R<sub>6</sub>, independently, is H, halo, -R, -C(=O)OH, -C(=O)OR, -C(=O)SH, -C(=O)SR, -C(=O)NRR', -ROH, -ROR', -RSR', -NHR, -RNR'R'', -RNHR', or -RSR', or R<sub>5</sub> and R<sub>6</sub> together are -ORO-. Preferably, R<sub>5</sub> is a substituent at 3'-C and R<sub>6</sub> is an optional substituent at 5'-C.

50 [0006] Another subset of the compounds of formula (I) are featured by that Ar<sub>3</sub> is furyl, and each of R<sub>5</sub> and R<sub>6</sub>, independently, is H, halo, -R, -C(=O)OH, -C(=O)OR, -C(=O)SH, -C(=O)SR, -C(=O)NRR', -ROH, -ROR', -RSR', -NHR, -RNR'R'', -RNHR', or -RSR', or R<sub>5</sub> and R<sub>6</sub> together are -ORO-. Preferably, R<sub>5</sub> is H and R<sub>6</sub> is a substituent at 5'-C.

55 [0007] Set forth below are some specific examples of the compounds which can be used to practice the method of this invention: 1-benzyl-3-(3'-ethoxycarbonyl)phenyl-indazole, 1-benzyl-3-(3'-hydroxymethyl)phenyl-indazole, 1-benzyl-3-(5'-diethylaminomethyl)furyl-indazole, 1-benzyl-3-(5'-methoxymethyl)furyl-indazole, 1-benzyl-3-(5'-hydroxymethyl)furyl-6-methyl-indazole, 1-benzyl-3-(5'-hydroxymethyl)-furyl-indazole, 1-benzyl-3-(5'-hydroxymethyl)-furyl-6-fluoro-indazole, 1-benzyl-3-(5'-hydroxymethyl)-furyl-6-methoxy-indazole, 1-benzyl-3-(5'-hydroxymethyl)-furyl-5,6-methylenedioxoindazole.

60 [0008] The structures of 1-benzyl-3-(3'-ethoxycarbonyl)phenyl-indazole and 1-benzyl-3-(5'-diethylaminomethyl)furyl-indazole are shown below with the atoms on the aryl groups numbered:



15 [0009] For brevity, the fused pyrazolyl compounds described above include their pharmaceutically acceptable salts, if applicable. Such a salt can be formed between an amino substituent and a negatively charged counterion. Suitable counterions include, but are not limited to, chloride, bromide, iodide, sulfate, nitrate, phosphate, or acetate. Likewise, a negatively charged substituent (e.g., carboxylate) can form a salt with a cation (e.g., sodium ion, potassium ion, magnesium ion, calcium ion, or an ammonium cation such as tetramethylammonium ion). Examples of salts to be used in the method of this invention include a hydrochloride salt of 1-benzyl-3-(5'-aminomethyl)furyl-indazole and a sodium salt of 1-benzyl-3-(3'-carboxyl)phenyl-indazole.

20 [0010] A fused pyrazolyl compound is formulated into a pharmaceutical composition before it is administered to a subject in need of treatment of an thrombin-induced disorder or disease (e.g., atherosclerosis, myocardial infarction, unstable angina pectoris and thrombosis). Thus, also within the scope of the invention is the composition which contains an effective amount of the compound (or its salt) and a pharmaceutically acceptable carrier for use in treating a disorder or disease aforementioned. Examples of the carriers include colloidal silicon dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and D&C Yellow # 10. The invention also relates to the use of such a composition for the manufacture of a medicament for the treatment of above-mentioned disorders or diseases.

25 [0011] It was unexpected that the method of this invention specifically inhibits thrombin-induced platelet aggregation, with no or little inhibitory effect on that induced by other platelet activators. Other advantages or features of the invention will be apparent from the following detailed description of several embodiments, and also from the appending claims.

#### Detailed Description of the Invention

30 [0012] This invention relates to using a fused pyrazolyl compound to treat a disorder or disease caused by thrombin-induced platelet aggregation.


35 [0013] A method of synthesizing the fused pyrazolyl compound is as follows: An aryl aryl ketone is first prepared by coupling an arylcarbonyl chloride with another aryl compound. Either aryl compound is optionally mono- or multi-substituted. The ketone then reacts with an arylalkylhydrazine, the aryl group of which is also optionally mono- or multi-substituted, to form a hydrazone containing three aryl groups. The hydrazone is transformed into a fused pyrazolyl compound. In the fused pyrazolyl compound, an aryl group is connected to 1-N of the pyrazolyl core via an alkylene linker, another aryl group is fused at 4-C and 5-C of the pyrazolyl core, and the third aryl group is directly connected to 3-C of the pyrazolyl core. Derivatives of the fused pyrazolyl compound may be obtained by modifying the substituents on any of the aryl groups.

40 [0014] Synthesis of three types of fused pyrazolyl compounds, i.e., 1-benzyl-3-furyl-indazole, 1-benzyl-3-phenyl-pyrazole, and thiencylpyrazole, in the method is described in detail below.

45 [0015] Shown in Scheme 1 below is a method of synthesizing five 1-benzyl-3-furyl-indazole compounds, indicated as (1) - (5), all of which can be used to practice the method of the invention.

50

55



### Scheme 1

55

[0016] As shown in Scheme 1, 5'-methoxycarbonyl-2-furyl phenyl ketone, prepared by coupling methyl 2-furoate with benzoyl chloride, reacts with benzylhydrazine to form a benzylhydrazone as a mixture of E- and Z- form isomers. The isoform mixture is then treated with a mixture of  $Pb(OAc)_4$  and  $BF_3 \cdot Et_2O$  in  $CH_2Cl_2$  at room temperature, via a

same azo intermediate, to give compound (1). The methoxycarbonyl group in compound (1) can be hydrolyzed with NaOH to carboxylic acid group to form compound (2). Alternatively, the methoxycarbonyl group can be reduced with Ca(BH<sub>4</sub>)<sub>2</sub> in THF to hydroxymethyl group to form compound (3). Compound (3) can be successively treated with BCl<sub>3</sub> and diethylamine to obtain an N,N-diethylaminomethyl derivative, i.e., compound (4). Optionally, compound (3) can also be successively treated with BCl<sub>3</sub> and methanol to obtain a methoxymethyl derivative, i.e., compound (5). Although not shown in the scheme, derivatives of compounds (1) - (5) can be obtained by using other 2-furoates, benzoyl chlorides, or benzylhydrazones, in which the aryl group is mono- or multi-substituted.

[0017] 1-Benzyl-3-phenyl-indazole compounds can be prepared by following the same reaction procedure shown in Scheme 1 except that benzophenone, optionally mono- or multi-substituted, is used instead of 2-furyl phenyl ketone.

10 As an initial step, benzophenone is oxidized with CrO<sub>3</sub> to form benzoylbenzoic acid. The benzoylbenzoic acid is then treated with ethanol to form ethyl benzoylbenzoate, which can be transformed into 1-benzyl-3-phenyl-indazole. 1-Benzyl-3-phenyl-indazole can be further transformed into its derivatives by modifying the substituent(s) on the three aryl groups, if applicable.

15 [0018] Fused pyrazolyl compounds containing a thienopyrazole moiety can also be prepared by following the same synthetic method shown in Scheme 1, except that 2-thienyl aryl ketone; is used instead of 2-furyl phenyl ketone. The mono- or multi-substituents, if any, of the thienopyrazolyl compounds thus obtained, can be further modified to afford additional thienopyrazolyl compounds.

20 [0019] An effective amount of a fused pyrazolyl compound or its salt is formulated with a pharmaceutically acceptable carrier to form a pharmaceutical composition before administered to a subject in need of treatment of a disorder or disease related to thrombin-induced platelet aggregation. "An effective amount" refers to the amount of the compound which is required to confer therapeutic effect on the treated subject. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al., Cancer Chemother. Rep., 1966, 50, 219. Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardley, N.Y., 1970, 537. Effective doses will also vary, as recognized by those skilled in the art, depending on route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatments including use of other anti-platelet aggregation agents.

25 [0020] The pharmaceutical composition may be administered via a parenteral route, e.g., topically, subcutaneously, intraperitoneally, intramuscularly, and intravenously. Examples of parenteral dosage forms include aqueous solutions of the active compound, in an isotonic saline, 5% glucose, or any other well-known pharmaceutically acceptable carrier. Solubilizing agents, such as cyclodextrins, or other solubilizing agents well known to those familiar with the art, can also be included in the pharmaceutical composition.

30 [0021] A fused pyrazolyl compound to be used to practice the method of the invention can be formulated into dosage forms for other routes of administration (e.g., orally, mucosally, or percutaneously) utilizing well known methods. The pharmaceutical composition can be formulated, for example, in dosage forms for oral administration in a capsule, a gel seal, or a tablet. Capsules may comprise any well known pharmaceutically acceptable material such as gelatin or cellulose derivatives. Tablets may be formulated in accordance with the conventional procedure by compressing mixtures of the active compounds, a solid carrier, and a lubricant. Examples of solid carriers include starch and sugar bentonite. The compound can also be administered in a form of a hard shell tablet or capsule containing, for example, lactose or mannitol as a binder, a conventional filler, and a tableting agent.

35 [0022] A suitable *in vitro* inhibition assay can be used to preliminarily evaluate a fused pyrazolyl compound's ability to inhibit thrombin-induced platelet aggregation. For example, a platelet suspension in Tyrode's solution can be prepared and incubated with a compound to be tested, thrombin added to trigger platelet aggregation, and the aggregation measured turbidimetrically with a light-transmission aggregometer. *In vivo* screening can be performed by following procedures well known in the art.

40 [0023] Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. All publications recited herein are hereby incorporated by reference in their entirety. The following specific examples, which describe synthesis and biological testing of various compounds of the present invention, are therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

45

#### Example 1:

##### Synthesis of 1-benzyl-3-(5'-methoxycarbonyl-2'-furyl)indazole

50 (a) Synthesis of 5-methoxycarbonyl-2-furyl phenyl ketone

[0024] Anhydrous ferric chloride (0.42 g, 2.6 mmole) and benzoyl chloride (29.6 g, 0.21 mole), were dissolved in CCl<sub>4</sub> (40 mL) and added dropwise over 10 min with methyl-2-furoate (25.2 g, 0.20 mmole). The reaction mixture was

then heated under reflux for 36 hrs, and after cooling was added with water (120 mL). The mixture was stirred for 1 hr and then allowed to sit until it separated into two layers. The water layer and precipitate were extracted with chloroform. The chloroform extract was dried over anhydrous magnesium sulfate and then filtered. The solvent of the filtrate was removed under a reduced pressure; the residue was recrystallized from isopropanol to afford 28.4 g 5-methoxycarbonyl-2-furyl phenyl ketone at a yield of 65.0%.

5 mp: 70-73°C.

10 MS (%), m/z: 230 (M<sup>+</sup>).

15 IR (KBr)  $\nu_{\text{max}}$ : 1720, 1650 cm<sup>-1</sup> (C=O).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 200 MHz) δ: 3.86 (3H, s, -CH<sub>3</sub>), 7.26-7.32 (2H, m, H-3',5'), 7.40-7.65 (3H, m, H-3,4,4'), 8.05-8.10 (2H, m, H-2', 6').

15 (b) Synthesis of 1-benzyl-3-(5'-methoxycarbonyl-2'-furyl)indazole

[0025] 5-Methoxycarbonyl-2-furyl phenyl ketone (5.5 g, 0.024 mole) was dissolved in methanol (60 mL), added with benzylhydrazine (9 g, 0.07 mole) and acetic acid (0.5 mL) and then heated under reflux till the reaction was completed. After cooling, the solvent was evaporated. The resultant residue was extracted with chloroform and washed with dilute HCl solution, then water, and then dried over anhydrous magnesium sulfate and filtered. The solvent of the filtrate was removed to give 5-methoxycarbonylfuryl phenyl ketone benzylhydrazone.

[0026] A solution of hydrazone thus obtained in dichloromethane (100 mL) was added dropwise to the solution of Pb(OAc)<sub>4</sub> (28.2g, 0.06mole) in dichloromethane (400 mL). After addition, the mixture was allowed to react at 30±2°C for 30 min, and BF<sub>3</sub>Et<sub>2</sub>O (containing 47% of BF<sub>3</sub>, 122 mL) was added. The mixture was heated under reflux for 30 min and then poured into ice water (1000 mL) to terminate the reaction. The organic layer was separated and washed sequentially with water and 10% sodium carbonate solution, then neutralized by water wash. It was dried over anhydrous magnesium sulfate and was concentrated under vacuum to an oily crude product. Ethanol was then added to the crude product, and the mixture was allowed to precipitate by freeze overnight. The solid precipitate was collected and recrystallized from ethanol to give 3.7 g 1-benzyl-3-(5'-methoxycarbonyl-2'-furyl)indazole at a yield of 47.0%.

mp: 117-118°C.

35 MS (%), m/z: 332 (M<sup>+</sup>).

IR (KBr)  $\nu_{\text{max}}$ : 1720 cm<sup>-1</sup> (C=O).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 3.95 (3H, s, CH<sub>3</sub>), 5.66 (2H, s, =NCH<sub>2</sub>-), 7.02 (1H, d, J=3.5 Hz, H-3'), 7.20-7.40 (9H, m, H-5, 6, 7, 4', phenyl), 8.26 (1H, dd, J=8.1, 1.5 Hz, H-4).

40 Example 2:

Synthesis of 1-benzyl-3-(5'-methoxycarbonyl-2'-furyl)-6-fluoroindazole

[0027] 4'-Fluorophenyl 5-methoxycarbonyl-2-furyl ketone (5.96 g, 24 mmole) was prepared as in Example 1 (a), and used as the starting material to obtain 4.1g 1-benzyl-3-(5'-methoxycarbonyl-2'-furyl)-6-fluoroindazole at a yield of 48.8%, according to the procedure described in Example 1(b).

45 mp: 108-109°C.

50 MS (%), m/z: 350 (M<sup>+</sup>).

IR (KBr)  $\nu_{\text{max}}$ : 1710 cm<sup>-1</sup>(C=O).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz) δ: 3.87 (3H, s, -CH<sub>3</sub>), 5.73 (2H, s, =NCH<sub>2</sub>-), 7.18-7.37 (7H, m, H-5,3', phenyl), 7.45 (1H, d, J=3.5 Hz, H-4), 7.77 (1H, dd, J=10.0, 1.5 Hz, C7-H), 8.17 (1H, dd, J=8.0, 6.3 Hz, C4-H).

**Example 3:**

Synthesis of 1-benzyl-3-(5-methoxycarbonyl-2'-furyl)-6-methylindazole

5 [0028] 5-Methoxycarbonyl-2-furyl 4'-methylphenyl ketone (5.85 g, 0.024 mole) was similarly prepared and used as the starting material to obtain 3.7 g 1-benzyl-3-(5-methoxycarbonyl-2'-furyl)-6-methylindazole at a yield of 45.1%.

mp: 102-104°C.

MS (%), m/z: 346 (M<sup>+</sup>)

10 IR (KBr)  $\nu_{\text{max}}$ : 1720 cm<sup>-1</sup> (C=O).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 2.46 (3H, s, -CH<sub>3</sub>), 3.87 (3H, s, -OCH<sub>2</sub>-), 5.71 (2H, s, =NCH<sub>2</sub>-), 7.14-7.36 (7H, m, H-5, 3'', phenyl), 7.45 (1H, d, J=3.4 Hz, H-4); 7.59 (1H, s, H-7); 8.10 (1H, d, J=8.0 Hz, H-4).

**Example 4:**

15 Synthesis of 1-benzyl-3-(5'-methoxycarbonyl-2'-furyl)-6-methoxyindazole

[0029] 5-Methoxycarbonyl-2-furyl 4'-methoxyphenyl ketone (6.24 g, 0.024 mole) was similarly prepared and used as the starting material to obtain 4.4g 1-benzyl-3-(5'-methoxycarbonyl-2'-furyl)-6-methoxyindazole at a yield of 50.2%.

20 mp: 108-109°C

MS (%), m/z: 362 (M<sup>+</sup>)

IR (KBr)  $\nu_{\text{max}}$ : 1710 cm<sup>-1</sup> (C=O).

25 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz)  $\delta$ : 3.85 (3H, s, -OCH<sub>3</sub>), 3.88 (3H, s, -COOCH<sub>3</sub>), 5.71 (2H, s, =NCH<sub>2</sub>-), 6.95 (1H, d, J=8.5 Hz, H-5), 7.16 (1H, d, J=3.5 Hz, H-3'), 7.24-7.36 (6H, m, H-7, phenyl), 7.40 (1H, d, J=3.5 Hz, H-4), 7.98 (1H, d, J=8.5 Hz, H-4).

**Example 5:**

30 Synthesis of 1-benzyl-3-(5'-methoxycarbonyl-2'-furyl)-5,6-methylenedioxoindazole

[0030] 5-Methoxycarbonyl-2-furyl-3', 4'-methylenedioxophenyl ketone (6.6 g, 0.024 mole) was similarly prepared and used as the starting material to obtain 5.7 g 1-benzyl-3-(5'-methoxycarbonyl-2'-furyl)-5,6-methylenedioxoindazole at a yield of 63.8%.

35 mp: 190-192°C

MS (%), m/z: 376 (M<sup>+</sup>)

IR (KBr)  $\nu_{\text{max}}$ : 1724 cm<sup>-1</sup> (C=O).

40 <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 200 MHz)  $\delta$ : 3.93 (3H, s, -OCH<sub>3</sub>), 5.51 (2H, s, =NCH<sub>2</sub>-), 5.98 (2H, s, -OCH<sub>2</sub>O-), 6.62 (1H, s, H-7), 6.91 (1H, d, J=3.8 Hz, H-3'), 7.18-7.32 (6H, m, H-4', phenyl), 7.52 (1H, s, H-4).

**Example 6:**

Synthesis of 1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)indazole

45 [0031] 1-Benzyl-3-(5'-methoxycarbonyl-2'-furyl)indazole (100 mg, 0.32 mmole) was dissolved in a mixture of methanol (8 mL) and sodium hydroxide solution (75 mg in 3 mL water) then heated under reflux. After cooling, the solvent was removed under a reduced pressure. The residue was dissolved in water (1.5 mL), and the aqueous solution was acidified with a diluted HCl solution to generate a crystal. The crystal was collected, and then recrystallized from acetone to obtain 73 mg 1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)indazole at a yield of 71.7%.

mp: 202-203°C.

MS (%), m/z: 318 (M<sup>+</sup>)

IR (KBr)  $\nu_{\text{max}}$ : 3450 cm<sup>-1</sup>(-OH), 1700 cm<sup>-1</sup>(C=O).

55 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz)  $\delta$ : 5.76 (2H, s, =NCH<sub>2</sub>-), 7.20 (1H, d, J=3.5 Hz, H-3'), 7.26-7.35 (6H, m, H-5, phenyl), 7.38 (1H, d, J=3.5 Hz, H-4'), 7.49 (1H, t, J=8.2 Hz, H-6), 7.80 (1H, dd, J=8.2, 1.5 Hz, H-7), 8.15 (1H, d, J=8.1, 1.5 Hz, H-4).

**Example 7:****Synthesis of 1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)-6-fluoroindazole**

5 [0032] 1-Benzyl-3-(5'-methoxycarbonyl-2'-furyl)-6-fluoroindazole (112 mg, 0.32 mmole) was used as the starting material and treated according to the procedure described in Example 6 to obtain 70 mg 1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)-6-fluoroindazole at a yield of 65%.

mp: 252-253°C.

10 MS (%), m/z: 336 (M<sup>+</sup>).

IR (KBr)  $\nu_{\text{max}}$ : 3450 cm<sup>-1</sup> (-OH), 1690 cm<sup>-1</sup> (C=O).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz) δ: 5.72 (2H, s, =NCH<sub>2</sub>-), 7.21 (1H, d, J=3.5 Hz, H-3), 7.23-7.33 (6H, m, H-5, phenyl), 7.39 (1H, d, J=3.5 Hz, H-4), 7.79 (1H, dd, J=9.8, 1.8 Hz, H-7), 8.17 (1H, dd, J=8.5, 5.3 Hz, H-4).

**Example 8:****Synthesis of 1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)-6-methylindazole**

20 [0033] 1-Benzyl-3-(5'-methoxycarbonyl-2'-furyl)-6-methylindazole (111 mg, 0.32 mmole) was used as the starting material and treated according to the procedure described in Example 6 to obtain 95 mg 1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)-6-methylindazole at a yield of 89%.

mp: 201-202°C

25 MS (%), m/z: 332 (M<sup>+</sup>).

IR (KBr)  $\nu_{\text{max}}$ : 3450 cm<sup>-1</sup> (-OH), 1700 cm<sup>-1</sup> (C=O).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz) δ: 2.46 (3H, s, -CH<sub>3</sub>), 5.70 (2H, s, =NCH<sub>2</sub>-), 7.16 (1H, d, J=3.5 Hz, H-3'), 7.23-7.33 (6H, m, H-5, phenyl), 7.38 (1H, d, J=3.5 Hz, H-4), 7.61 (1H, d, J=1.4 Hz, H-7), 8.00 (1H, d, J=8.2 Hz, H-4).

**Example 9:**

30

**Synthesis of 1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)-6-methoxyindazole**

[0034] 1-Benzyl-3-(5'-methoxycarbonyl-2'-furyl)-6-methoxyindazole (116 mg, 0.32 mmole) was used as the starting material and treated according to the procedure described in Example 6 to obtain 88.1 mg 1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)-6-methoxyindazole at a yield of 77.3%.

mp: 222-223°C.

MS (%), m/z: 348 (M<sup>+</sup>)

IR (KBr)  $\nu_{\text{max}}$ : 3450 cm<sup>-1</sup> (-OH), 1710 cm<sup>-1</sup> (C=O)

40 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz) δ: 3.84 (3H, s, -OCH<sub>3</sub>), 5.70 (2H, s, =NCH<sub>2</sub>-), 6.95 (1H, dd, J=8.3, 1.8 Hz, H-3'), 7.12 (1H, d, J=3.4 Hz, H-3), 7.25-7.38 (7H, m, H-7, 4', phenyl), 7.98 (1H, d, J=8.3 Hz, H-4).

**Example 10:**

45

**Synthesis of 1-benzyl-3-(5'-hydroxycarbonyl-2-furyl)-5,6-methylenedioxoindazole**

[0035] 1-Benzyl-3-(5'-methoxycarbonyl-2'-furyl)-5,6-methylenedioxoindazole (120 mg, 0.32 mmole) was used as the starting material and treated according to the procedure described in Example 6 to obtain 87.5 mg 1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)-5,6-methylenedioxoindazole at a yield of 75.5%.

50 mp: 291-292°C.

MS (%), m/z: 362 (M<sup>+</sup>)

IR (KBr)  $\nu_{\text{max}}$ : 3479 cm<sup>-1</sup> (-OH), 1720 cm<sup>-1</sup> (C=O)

55 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz) δ: 5.62 (2H, s, =NCH<sub>2</sub>-), 6.11 (2H, s, -OCH<sub>2</sub>O-), 7.09 (1H, d, J=3.6, H-3'), 7.20-7.36 (7H, m, H-7, 4', phenyl), 7.43 (1H, s, H-4).

**Example 11:**

## Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole

5 [0036] Calcium borohydride was first prepared by stirring anhydrous calcium chloride (88.8 mg, 0.8 mmole) with sodium borohydride (60 mg, 1.6 mmole) in anhydrous THF (20 mL) for 4 hrs. Then a 30 mL THF solution containing 88.0 mg 1-benzyl-3-(5'-methoxycarbonyl-2'-furyl)indazole (0.27 mmole) was added dropwise to the calcium borohydride solution at 30±2 °C. The mixture was heated under reflux for 6 hrs, cooled, quenched into crushed ice, placed at a reduced pressure to remove THF, and filtered to obtain a solid product. The solid was extracted with dichloromethane. The extract was concentrated to 50 mL and a solid precipitated after petroleum ether was added. The precipitate was collected and purified by column chromatography (silica gel-benzene) to obtain 70.0 mg 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole at a yield of 87%.

15 mp: 108-109°C.  
 MS (%), m/z: 304 (M<sup>+</sup>).  
 IR (KBr) ν<sub>max</sub>: 3350 cm<sup>-1</sup> (-OH).  
<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz) δ: 4.51 (2H, d, J=5.5 Hz, -CH<sub>2</sub>O-), 5.31 (1H, t, J=5.5 Hz, -OH), 5.70 (2H, s, =NCH<sub>2</sub>-), 6.48 (1H, d, J=3.4 Hz, H-4'), 6.97 (1H, d, J=3.4 Hz, H-3'), 7.21-7.31 (6H, m, H-5, phenyl), 7.45 (1H, t, J=8.2 Hz, H-6), 7.75 (1H, dd, J=8.2, 1.8 Hz, H-7), 8.12 (1H, dd, J=8.2, 1.0 Hz, C4-H).

**Example 12:**

## Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)-6-fluoroindazole

25 [0037] 1-Benzyl-3-(5'-methoxycarbonyl-2'-furyl)-6-fluoroindazole (93 mg, 0.27 mmole) was used as the starting material and treated according to the procedure described in Example 11 to obtain 75.0 mg 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)-6-fluoroindazole

30 at a yield of 88.0%.  
 mp: 110-112°C.  
 MS (%), m/z: 322 (M<sup>+</sup>).  
 IR (KBr) ν<sub>max</sub>: 3450 cm<sup>-1</sup> (-OH).  
<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz) δ: 4.49 (2H, br, -CH<sub>2</sub>O-), 5.45 (1H, br, -OH), 5.88 (1H, s, =NCH<sub>2</sub>-), 6.48 (1H, d, J=3.2 Hz, H-4'), 6.98 (1H, d, J=3.2 Hz, H-3'), 7.10-7.18 (1H, m, H-7), 7.24-7.36 (5H, m, phenyl-H), 7.70 (1H, dd, J=10.0, 2.0 Hz, C5-H), 8.15 (1H, dd, J=8.5, 5.1 Hz, H-4).

**Example 13:**

## Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)-6-methylindazole

40 [0038] 1-Benzyl-3-(5'-methoxycarbonyl-2'-furyl)-6-methylindazole (92 mg, 0.27 mmole) was used as the starting material and treated according to the procedure described in Example 11 to obtain 74.0 mg 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)-6-methylindazole at a yield of 88%.

45 mp: 112-114°C.  
 MS (%), m/z: 318 (M<sup>+</sup>).  
 IR (KBr) ν<sub>max</sub>: 3400 cm<sup>-1</sup> (-OH).  
<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz) δ: 2.44 (3H, s, -CH<sub>3</sub>), 4.50 (2H, d, J=5.2 Hz, -CH<sub>2</sub>O-), 5.30 (1H, br, -OH), 5.64 (2H, s, =NCH<sub>2</sub>-), 6.45 (1H, d, J=3.3 Hz, H-4'), 6.07 (1H, d, J=3.3 Hz, H-3'), 7.08 (1H, dd, J=8.3, 1.0 Hz, H-5), 7.19-7.36 (5H, m, phenyl-H), 7.57 (1H, d, J=1.0 Hz, H-7), 7.98 (1H, dd, J=8.3, 1.0 Hz, H-4).

**Example 14:**

## Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)-6-methoxyindazole

55 [0039] 1-Benzyl-3-(5'-methoxycarbonyl-2'-furyl)-6-methoxyindazole (96 mg, 0.27 mmole) was used as the starting material and treated according to the procedure described in Example 11 to obtain 80 mg 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)-6-methoxyindazole at a yield of 90%.

mp: 109-110°C

MS (%), m/z: 334 (M<sup>+</sup>).

IR (KBr)  $\nu_{\text{max}}$ : 3300-3400 cm<sup>-1</sup> (-OH).

<sup>5</sup> <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 200 MHz) δ: 1.90 (1H, br, -OH), 3.80 (3H, s, -CH<sub>3</sub>), 4.74 (2H, d, J=4.9 Hz, -CH<sub>2</sub>O-), 5.59 (2H, s, =NCH<sub>2</sub>-), 6.47 (1H, d, J=3.2 Hz, H-4'), 6.59 (1H, d, J=2.0 Hz, H-7), 6.84 (1H, d, J=3.2, 1.0 Hz, H-3'), 6.88 (1H, dd, J=8.5, 1.5 Hz, H-5), 7.17-7.31 (5H, m, phenyl-H), 7.91 (1H, d, J=8.5 Hz, H-4).

#### Example 15:

##### Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)-5,6-methylenedioxoindazole

[0040] 1-Benzyl-3-(5'-methoxycarbonyl-2'-furyl)-5,6-methylenedioxoindazole (101 mg, 0.27 mmole) was used as the starting material and treated according to the procedure described in Example 11 to obtain 84.5 mg 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)-5,6-methylenedioxoindazole at a yield of 90%.

mp: 122-123°C.

MS (%), m/z: 348 (M<sup>+</sup>).

IR (KBr)  $\nu_{\text{max}}$ : 3387 cm<sup>-1</sup> (-OH).

<sup>15</sup> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 2.05 (1H, br, -OH), 4.71 (2H, s, -CH<sub>2</sub>O-), 5.53 (2H, s, =NCH<sub>2</sub>-), 5.99 (2H, s, -OCH<sub>2</sub>O-), 6.43 (1H, d, J=3.3 Hz, H-4'), 6.61 (1H, s, H-7), 6.76 (1H, d, J=3.3 Hz, H-3'), 7.20-7.31 (6H, m, H-4, phenyl).

#### Example 16:

##### Synthesis of 1-benzyl-3-(5'-methoxymethyl-2'-furyl)indazole

[0041] To a solution of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (0.2g, 0.66 mmole) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (5ml) was added 1.0 M BCl<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub> solution (1.5 mL) at -10±2°C. The mixture was allowed to react for 4 hrs at this temperature. Then, methanol (5ml) was added and the stirring continued for another 1 hrs before quenched into ice water. The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the organic extract was neutralized by water wash, dried over anhydrous magnesium sulfate and evaporated for solvent removal and purified by column chromatography (silica gel-benzene) to obtain 0.1g 1-benzyl-3-(5'-methoxymethyl-2'-furyl)indazole in liquid at a yield 50%.

MS (%), m/z: 318 (M<sup>+</sup>).

IR (KBr)  $\nu_{\text{max}}$ : 1610 cm<sup>-1</sup> (C-O).

<sup>35</sup> <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 200 MHz) δ: 3.45 (3H, s, -CH<sub>2</sub>OCH<sub>3</sub>), 4.56 (3H, s, -CH<sub>2</sub>OCH<sub>3</sub>), 5.29 (2H, s, =NCH<sub>2</sub>-), 6.52 (1H, d, J=3.3 Hz, H-4'), 6.91 (1H, d, J=3.3 Hz, H-3'), 7.18-7.36 (8H, m, H-5,6,7,phenyl), 8.12 (1H, dd, J=8.1, 1.1 Hz, H-4).

#### Example 17:

##### Synthesis of 1-benzyl-3-(5'-diethylaminomethyl-2'-furyl)indazole

[0042] To a solution of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (1.0 g, 3.3 mmole) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) was added dropwise 1.0 M BCl<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub> solution (20 mL) at -10±2°C. The mixture was allowed to react for 40 min at this temperature.

[0043] <sup>45</sup> The diethylamine (30 mL) was added, and the mixture was brought to reflux for 4 hrs followed by quenched into ice water. The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic extract was neutralized by water wash, dried over anhydrous magnesium sulfate and evaporated to leave a residue which upon purification by column chromatography (silica gel-benzene) afforded 0.16g 1-benzyl-3-(5'-diethylaminomethyl-2'-furyl)indazole at a yield of 39.0%.

MS (%), m/z: 359 (M<sup>+</sup>).

IR (KBr)  $\nu_{\text{max}}$ : 1350 cm<sup>-1</sup> (C-N).

<sup>55</sup> <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 200 MHz) δ: 1.16 (6H, t, J=7.1 Hz, -N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>), 2.63 (4H, q, J=7.1 Hz, -N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>), 3.86 (2H, s, -CH<sub>2</sub>N-), 5.64 (2H, s, =NCH<sub>2</sub>-), 6.37 (1H, d, J=3.3 Hz, H-4'), 6.87 (1H, d, J=3.3 Hz, H-3'), 7.10-7.40 (8H, m, H-5,6,7,phenyl), 8.10 (1H, d, J=8.2 Hz, H-4).

**Example 18:**

Synthesis of 1-benzyl-3-(4'-ethoxycarbonylphenyl)indazole

5 [0044]

- (a) To the mixture of anhydrous  $\text{AlCl}_3$  (85 g, 0.64 mole) with dried toluene (90 mL) was added benzoyl chloride (50 mL, 0.43 mole) dropwise at  $10\pm 2^\circ\text{C}$ . The mixture was warmed to  $30\pm 2^\circ\text{C}$  and stirred for 12 hrs, and then heated to  $100\pm 5^\circ\text{C}$  and stirred for another 2 hr before cooled and adding ice water (200 mL) to terminate the reaction. The organic layer was separated and washed successively with water, 5% sodium carbonate and then water again till neutralized. The organic layer was dried over anhydrous magnesium sulfate and evaporated. The residue was recrystallized from n-hexane to obtain 62.1 g 4-methylbenzophenone at a yield 73.5%.  
mp: 55-57°C
- (b) To a mixture of 4-methylbenzophenone (25 g, 0.127 mole) with HOAc (130 mL) was added successively  $\text{CrO}_3$  (35 g),  $\text{H}_2\text{O}$  (80 mL) and conc.  $\text{H}_2\text{SO}_4$  (25 mL). The mixture was heated for 3 hrs at  $100\pm 5^\circ\text{C}$  and then quenched by adding ice water (500 mL) to yield a crude 4-benzoylbenzoic acid solid which was dissolved in 10% KOH and filtered. The filtrate was acidified with diluted HCl to pH 2.0 and precipitate by subjected to ice bath. The precipitate was collected to obtain 21.3 g 4-benzoylbenzoic acid at a yield of 74.1%.
- (c) A mixture of 4-benzoylbenzoic acid (20 g, 88.4 mmole), toluene (5 ml), p-toluenesulfonic acid (1 g) and ethanol (20 mL) was refluxed for 12 hrs, cooled, washed with 5% sodium carbonate and neutralized by water wash. The organic layer was dried over anhydrous magnesium sulfate and concentrated to obtain 22 g ethyl 4-benzoylbenzoate at a yield 90.5%.
- (d) A mixture of ethyl 4-benzoylbenzoate (13.7 g, 54 mmole), benzylhydrazine (8 g, 65 mmole), ethanol (50 mL) and HOAc (1 mL) was refluxed for 12 hrs and then treated with the same procedure as in Example 1 to yield a crude product that was purified by column chromatography (silica gel-benzene), and recrystallized from n-hexane to give 4.8g 1-benzyl-3-(4'-ethoxycarbonylphenyl)indazole at a yield of 25.5%.

mp: 95-96°C.

IR (KBr)  $\nu_{\text{max}}$ : 1710, 1620  $\text{cm}^{-1}$  (C=O).

MS (%), m/z: 356 ( $\text{M}^+$ ).

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 200 MHz)  $\delta$ : 1.35 (3H, t,  $J=8.0$  Hz,  $-\text{CH}_2\text{CH}_3$ ), 4.35 (2H, q,  $J=8.0$  Hz,  $-\text{CH}_2\text{CH}_3$ ), 5.78 (2H, s,  $=\text{NCH}_2-$ ), 7.40-8.40 (13H, m, aromatic protons).

**Example 19:**

35

Synthesis of 1-benzyl-3-(3'-ethoxycarbonylphenyl)indazole

[0045] 3-Methylbenzophenone was treated sequentially with the procedures (a), (b), (c), and (d) in Example 18 to obtain, in the corresponding order, 3-benzoylbenzoic acid (yield: 72%), ethyl 3-benzoylbenzoate (yield: 86.3%), and 1-benzyl-3-(3'-ethoxycarbonylphenyl)indazole at a yield of 25.5%.

mp: 85-86°C.

MS (%), m/z: 356 ( $\text{M}^+$ ).

IR (KBr)  $\nu_{\text{max}}$ : 1720, 1610  $\text{cm}^{-1}$  (C=O).

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 200 MHz)  $\delta$ : 1.43 (3H, t,  $J=7.0$  Hz,  $-\text{CH}_2\text{CH}_3$ ), 4.44 (2H, q,  $J=7.0$  Hz,  $-\text{CH}_2\text{CH}_3$ ), 5.68 (2H, s,  $=\text{NCH}_2-$ ), 7.20-8.20 (13H, m, aromatic protons).

**Example 20:**

50

Synthesis of 1-benzyl-3-(4'-hydroxycarbonylphenyl)indazole

[0046] To a solution of 1-benzyl-3-(4'-ethoxycarbonylphenyl)indazole (1 g, 2.8 mmole) dissolved in 10 mL methanol was added sodium hydroxide solution (0.56 g in 20 mL water). After the mixture was heated under reflux for 6 hrs, methanol was removed by evaporation. The residue was acidified with diluted HCl. After cooling in an ice bath, a solid precipitated and was collected to obtain 0.87 g 1-benzyl-3-(4'-hydroxycarbonyl-phenyl)-indazole. 94.5%.

mp: 205-207°C.

MS (%), m/z: 328 ( $\text{M}^+$ ).

IR (KBr)  $\nu_{\text{max}}$ : 3500-3300 cm<sup>-1</sup> (OH), 1700 cm<sup>-1</sup> (C=O).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz)  $\delta$ : 5.77 (2H, s, =NCH<sub>2</sub>-), 7.20-8.20 (13H, m, aromatic protons), 13.0 (1H, br, -OH).

**Example 21:**

5

Synthesis of 1-benzyl-3-(3'-hydroxycarbonylphenyl)indazole

10

[0047] 1-Benzyl-3-(3'-ethoxycarbonylphenyl)indazole (0.49 g, 0.11 mmole) was treated following the same procedure described in Example 20 to obtain 0.83 g 1-benzyl-3-(3'-hydroxycarbonylphenyl)indazole at a yield of 90.2%.

15

mp: 190-192°C.

MS (%), m/z: 328 (M<sup>+</sup>).

IR (KBr)  $\nu_{\text{max}}$ : 3500-3300 cm<sup>-1</sup> (-OH), 1700 cm<sup>-1</sup> (C=O).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz)  $\delta$ : 5.76 (2H, s, =NCH<sub>2</sub>-), 7.20-8.20 (13H, m, aromatic protons).

15

**Example 22:**

20

Synthesis of 1-benzyl-3-(4'-hydroxymethylphenyl)indazole

25

[0048] 1-Benzyl-3-(4'-ethoxycarbonylphenyl)indazole (0.4 g, 1.2 mmole) was treated following the same procedure described in Example 12 to obtain 0.24 g 1-benzyl-3-(4'-hydroxymethylphenyl)indazole at a yield of 67.2%.

mp: 110-112°C.

MS (%), m/z: 314 (M<sup>+</sup>).

IR (KBr)  $\nu_{\text{max}}$ : 3300-2500 cm<sup>-1</sup> (OH).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz)  $\delta$ : 4.58 (2H, d, J=5.8 Hz, -CH<sub>2</sub>O-), 5.31 (1H, t, J=5.2 Hz, -OH), 5.73 (2H, s, =NCH<sub>2</sub>-), 7.20-8.20 (13H, m, aromatic protons).

30

**Example 23:**

35

Synthesis of 1-benzyl-3-(3'-hydroxymethylphenyl)indazole

35

[0049] 1-Benzyl-3-(3'-ethoxycarbonylphenyl)indazole (0.4 g, 1.2 mmole) was treated following the same procedure described in Example 12 to obtain 0.22 g 1-benzyl-3-(3'-hydroxymethylphenyl)indazole at a yield of 64.1%.

mp: 98-99°C.

MS (%), m/z: 314 (M<sup>+</sup>).

IR (KBr)  $\nu_{\text{max}}$ : 3300-2500 cm<sup>-1</sup> (OH).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz)  $\delta$ : 4.78 (2H, s, -CH<sub>2</sub>O-), 5.65 (2H, s, =NCH<sub>2</sub>-), 7.20-8.20 (13H, m, aromatic protons).

40

**Example 24:**

45

Synthesis of 1-benzyl-3-(5'-methoxycarbonyl-2'-furyl)thieno[3,2-c]pyrazole

45

(a) Synthesis of 5-methoxycarbonyl-2-furyl 2'-thienyl ketone

50

[0050] 2-Thiophenecarbonyl chloride (30.5 g, 0.21 mole), methyl 2-furoate (24 g, 0.19 mole), and anhydrous ferric chloride (0.42 g, 2.6 mmole) were allowed to react following the same procedure described in Example 1 to obtain 28.7 g 5-methoxycarbonyl-2-furyl 2'-thienyl ketone at a yield of 63.8%.

mp: 103-106°C.

MS (%), m/z: 236 (M<sup>+</sup>).

IR (KBr)  $\nu_{\text{max}}$ : 1720, 1620 cm<sup>-1</sup> (C=O).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 200 MHz)  $\delta$ : 3.98 (3H, s, -CH<sub>3</sub>), 7.22-7.31 (2H, m, H-3,4), 7.41 (1H, d, J=3.5 Hz, H-4'), 7.76 (1H, d, J=3.5 Hz, H-3'), 8.36 (1H, d, J=4.5 Hz, H-5).

## (b) Synthesis of 1-benzyl-3-(5'-methoxycarbonyl-2'-furyl)thieno[3,2-c]pyrazole

[0051] 5-Methoxycarbonyl-2-furyl 2'-thiophenyl ketone (5.7 g, 0.024 mole) was used as the starting material and treated following the same procedure described in Example 1 to obtain 1.2 g 1-benzyl-3-(5'-methoxycarbonyl-2'-furyl)thieno[3,2-c]pyrazole at a yield of 14.8%.

5 mp: 142-143°C.

MS (%), m/z: 338 (M<sup>+</sup>).

IR (KBr)  $\nu_{\text{max}}$ : 1720 cm<sup>-1</sup> (C=O).

10 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz) δ: 3.85 (3H, s, -CH<sub>3</sub>), 5.62 (2H, s, =NCH<sub>2</sub>-), 6.92 (1H, d, J=3.5 Hz, H-3'), 7.24 (1H, d, J= 4.8 Hz, H-6), 7.26-7.35 (5H, m, phenyl-H), 7.43 (1H, d, J=3.5 Hz, H-4'), 7.77 (1H, dd, J=4.8, 1.5 Hz, H-5).

**Example 25:**

## 15 Synthesis of 1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)thieno[3,2-c]pyrazole

[0052] 1-Benzyl-3-(5'-methoxycarbonyl-2'-furyl)thieno[3,2-c]pyrazole (108 mg, 0.32 mmole) was treated following the same procedure described in Example 6 to obtain 83.3 mg 1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)thieno[3,2-c]pyrazole at a yield of 80.3%.

20 mp: 221-224°C.

MS (%), m/z: 324 (M<sup>+</sup>).

IR (KBr)  $\nu_{\text{max}}$ : 3500 cm<sup>-1</sup> (-OH), 1720 cm<sup>-1</sup> (C=O).

25 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz) δ: 5.62 (2H, s, =NCH<sub>2</sub>-), 6.90 (1H, d, J=3.5 Hz, H-3'), 7.26 (1H, d, J=4.8 Hz, H-6), 7.25-7.35 (6H, m, H-4', phenyl), 7.78 (1H, d, J=4.8 Hz, C5-H).

**Example 26:**

## 30 Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)thieno[3,2-c]pyrazole

[0053] 1-Benzyl-3-(5'-methoxycarbonyl-2'-furyl)thieno[3,2-c]pyrazole (90 mg, 0.27 mole) was treated following the same procedure described in Example 11 to obtain 63.4 mg 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)thieno[3,2-c]pyrazole at a yield of 69.3%.

35 mp: 103-104°C.

MS (%), m/z: 310 (M<sup>+</sup>).

IR (KBr)  $\nu_{\text{max}}$ : 3360 cm<sup>-1</sup> (-OH).

40 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 200 MHz) δ: 4.46 (2H, d, J=5.3 Hz, -CH<sub>2</sub>O-), 5.27 (1H, t, J=5.3 Hz, -OH), 5.55 (2H, s, =NCH<sub>2</sub>-), 6.43 (1H, d, J=3.2 Hz, H-4'), 6.64 (1H, d, J=3.2 Hz, H-3'), 7.20 (1H, d, J=4.8 Hz, H-6), 7.27-7.35 (5H, m, phenyl-H), 7.72 (1H, d, J=4.8 Hz, H-5).

**Example 27:**

## 45 Screening for compounds capable of inhibiting thrombin-induced platelet aggregation

[0054] *In vitro* inhibitory activity of the fused pyrazoly compounds was preliminarily evaluated by the following method: A platelet suspension in Tyrode's solution was prepared according to a procedure described by Wu et al., Br. J. Pharm., 1995, 116, 1973-1978. Tyrode's solution has the following composition (mM): NaCl (136.8), KCl (2.8), NaHCO<sub>3</sub> (11.9), MgCl<sub>2</sub> (1.1), NaH<sub>2</sub>PO<sub>4</sub> (0.33), CaCl<sub>2</sub> (1.0), and glucose (11.2). The platelet number in the platelet suspension was adjusted to  $4.5 \times 10^8$  platelets/ml with the aid of a Coulter Counter (Model ZM). Each compound to be tested was added to an aliquot of the platelet suspension, which was then incubated at 37°C for 3 minutes under a stirring condition (1200 rpm) prior to addition of thrombin. Platelet aggregation was measured turbidimetrically with a light-transmission aggregometer. The extent of platelet aggregation was determined at 5 minutes after the addition of thrombin. The percentage of aggregation was calculated by the method described in Teng et al., Biochem. Biophys. Acta., 1987, 924, 375-382.

50 [0055] Compounds prepared in Examples 1-26 were tested and all showed inhibitory activity at different levels. For example, 1-benzyl-3-(5'-diethylaminomethyl)furyl-indazole unexpectedly showed much higher activity than a number of other compounds, e.g., 1-benzyl-3-(5'-hydroxymethyl)furyl-indazole. Further, 1-benzyl-3-(3'-ethoxycarbonyl)-phe-

nyl-indazole showed activity at least 10 times that of several other tested compounds, e.g., 1-benzyl-3-(4'-ethoxycarbonyl)phenyl-indazole. It also unexpectedly exerted little or no effect on platelet activating factors other than thrombin.

#### Other Embodiments

5

[0056] From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions, for example, aryl groups with three or more substituents. Thus, other embodiments are also within the claims.

10

#### Claims

15

1. Use of a compound having a pyrazolyl core; a first aryl group, via an alkylene linker, bonded to 1-N of the pyrazolyl core; a second aryl group fused at 4-C and 5-C of the pyrazolyl core; and a third aryl group bonded directly to 3-C of the pyrazolyl core; wherein each of the three aryl groups, independently, is phenyl, thienyl, furyl, or pyrrolyl, optionally substituted with halo, alkyl, carboxyl, alkoxy carbonyl, thiocarbonyl, aminocarbonyl, hydroxylalkyl, alkoxyalkyl, amino, aminoalkyl, thioalkyl, or alkylenedioxo; for the preparation of a medicament in an amount sufficient for treating a disorder or disease related to thrombin-induced platelet aggregation.


20

2. The use of claim 1, wherein the compound is of the following formula:

25

30

35



40

in which each of the first, second, and third aryl groups, Ar<sub>1</sub>, Ar<sub>2</sub>, and Ar<sub>3</sub>, independently, is phenyl, thienyl, furyl, or pyrrolyl; each of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub>, independently, is H, halo, -R, -C(=O)OH, -C(=O)OR, -C(=O)SH, -C(=O)SR, -C(=O)NRR', -ROH, -ROR', -RSR, -NRR', -NHR, -RNRR'R'', -RNHR', or -RSR'; or R<sub>1</sub> and R<sub>2</sub> together, R<sub>3</sub> and R<sub>4</sub> together, or R<sub>5</sub> and R<sub>6</sub> together are -ORO-, wherein each of R, R', and R'', independently, is C<sub>1-4</sub> alkyl; n is 1, or 2, or 3.

45

3. The use of claim 2, wherein Ar<sub>1</sub> is phenyl; Ar<sub>2</sub> is 6-substituted phenyl; and Ar<sub>3</sub> is 5'-substituted furyl or 3'-substituted phenyl.

4. The use of claim 2, wherein n is 1.

50

5. The use of claim 4, wherein Ar<sub>3</sub> is furyl and each of R<sub>5</sub> and R<sub>6</sub>, independently, is H, halo, -R, -C(=O)OH, -C(=O)OR, -C(=O)SH, -C(=O)SR, -C(=O)NRR', -ROH, -ROR', -RSR, -NRR', -NHR, -RNRR'R'', -RNHR', or -RSR'; or R<sub>5</sub> and R<sub>6</sub> together are -ORO-.

55

6. The use of claim 4, wherein Ar<sub>3</sub> is phenyl and each of R<sub>5</sub> and R<sub>6</sub>, independently, is H, halo, -R, -C(=O)OH, -C(=O)OR, -C(=O)SH, -C(=O)SR, -C(=O)NRR', -ROH, -ROR', -RSR, -NRR', -NHR, -RNRR'R'', -RNHR', or -RSR'; or R<sub>5</sub> and R<sub>6</sub> together are -ORO-.

7. The use of claim 6, wherein Ar<sub>3</sub> is phenyl, R<sub>5</sub> is H, and R<sub>6</sub> is at 4'-C.

8. The use of claim 6, wherein Ar<sub>3</sub> is phenyl, R<sub>5</sub> is at 3'-C, and R<sub>6</sub> is at 5'-C.
9. The use of claim 8, wherein R<sub>5</sub> is H, -C(=O)OH, -C(=O)OR, -C(=O)SH, -C(=O)SR, or -C(=O)NRR', and R<sub>6</sub> is H.
- 5 10. The use of claim 9, wherein R<sub>5</sub> is -C(=O)OR.
11. The use of claim 10, wherein R<sub>5</sub> is -C(=O)OEt.
12. The use of claim 11, wherein Ar<sub>2</sub> is phenyl and each of R<sub>3</sub> and R<sub>4</sub>, independently, is H, halo, -R, -C(=O)OH, -C(=O)OR, -C(=O)SH, -C(=O)SR, -C(=O)NRR', -ROH, -ROR', -RSR, -NRR', -NHR, -RNR'R'', -RNHR', or -RSR', or R<sub>3</sub> and R<sub>4</sub> together are -ORO-.
13. The use of claim 12, wherein Ar<sub>1</sub> is phenyl and each of R<sub>1</sub> and R<sub>2</sub>, independently, is H, halo, -R, -C(=O)OH, -C(=O)OR, -C(=O)SH, -C(=O)SR, -C(=O)NRR', -ROH, -ROR', -RSR, -NRR', -NHR, -RNR'R'', -RNHR', or -RSR', or R<sub>1</sub> and R<sub>2</sub> together are -ORO-.
14. The use of claim 13, wherein each of R<sub>1</sub> and R<sub>2</sub> is H.
15. The use of claim 14, wherein R<sub>3</sub> is at 5-C and R<sub>4</sub> is at 6-C.
- 20 16. The use of claim 15, wherein each of R<sub>3</sub> and R<sub>4</sub> is H.
17. The use of claim 5, wherein R<sub>5</sub> is H and R<sub>6</sub> is at 5'-C.
- 25 18. The use of claim 17, wherein R<sub>6</sub> is -R, -ROH, -ROR', -RSR, -NRR', -NHR, -RNR'R'', -RNHR', or -RSR'.
19. The use of claim 18, wherein Ar<sub>1</sub> is phenyl and each of R<sub>1</sub> and R<sub>2</sub>, independently, is H, halo, -R, -ROH, -ROR', -NH<sub>2</sub>, -NRR', -RSR', -OR, -OH, -SR, or -SH.
- 30 20. The use of claim 18, wherein Ar<sub>2</sub> is phenyl, R<sub>3</sub> is at 5-C, and R<sub>4</sub> is at 6-C.
21. The use of claim 20, wherein Ar<sub>1</sub> is phenyl and each of R<sub>1</sub> and R<sub>2</sub>, independently, is H, halo, -R, -ROH, -ROR', -NH<sub>2</sub>, -NRR', -RSR', -OR, -OH, -SR, or -SH.
- 35 22. The use of claim 21, wherein each of R<sub>1</sub> and R<sub>2</sub> is H.
23. The use of claim 22, wherein R<sub>6</sub> is -CH<sub>2</sub>OH.
24. The use of claim 23, wherein R<sub>3</sub> is H.
- 40 25. The use of claim 24, wherein R<sub>4</sub> is -CH<sub>3</sub>.
26. The use of claim 24, wherein R<sub>4</sub> is -OCH<sub>3</sub>.
27. The use of claim 22, wherein R<sub>6</sub> is -CH<sub>2</sub>OCH<sub>3</sub>.
- 45 28. The use of claim 27, wherein each of R<sub>3</sub> and R<sub>4</sub> is H.
29. The use of claim 22, wherein R<sub>6</sub> is -CH<sub>2</sub>NEt<sub>2</sub>.
- 50 30. The use of claim 29, wherein each of R<sub>3</sub> and R<sub>4</sub> is H.



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 01 11 3662

DOCUMENTS CONSIDERED TO BE RELEVANT									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IntCl.7)						
X	EP 0 667 345 A (YUNG SHIN PHARM. IND. CO. LTD.) 16 August 1995 (1995-08-16) * claims 1-12 * * page 3, line 1 - line 13 * ---	1-24	A61K31/415 C07D231/54 A61P7/02 A61P9/10						
X	WO 98 16223 A (BAYER AG) 23 April 1998 (1998-04-23) * page 3, line 1 - line 6 * * claims 1-9 *	1-6, 8, 9, 12-24							
X, D	WU CH-CH ET AL: "GAMMAC-1 INHIBITED HUMAN PLATELET AGGREGATION THROUGH NO-INDEPENDENT ACTIVATION OF SOLUBLE GUANYLATE CYCLASE" BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 116, no. 3, 1995, pages 1973-1978, XP002056083 ISSN: 0007-1188 * abstract *	1, 2, 4, 5, 17-19, 21-24							
X	YU S-M ET AL: "INHIBITION OF PLATELET FUNCTION BY A02131-1, A NOVEL INHIBITOR OF CGMP-SPECIFIC PHOSPHODIESTERASE, IN VITRO AND IN VIVO" BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 87, no. 9, 1 May 1996 (1996-05-01), pages 3758-3767, XP002056082 ISSN: 0006-4971 * abstract * * page 3758, left-hand column - page 3759, left-hand column * * page 3766, left-hand column, last paragraph * --- -/-	1, 2, 4, 5, 17-19, 21-24	TECHNICAL FIELDS SEARCHED (IntCl.7) A61K C07D						
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 33%;">Examiner</td> </tr> <tr> <td>BERLIN</td> <td>23 October 2001</td> <td>Siatou, E</td> </tr> </table> <p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone  Y : particularly relevant if combined with another document of the same category  A : technological background  O : non-written disclosure  P : intermediate document</p> <p>T : theory or principle underlying the invention  E : earlier patent document, but published on, or after the filing date  D : document cited in the application  L : document cited for other reasons  B : member of the same patent family, corresponding document</p>				Place of search	Date of completion of the search	Examiner	BERLIN	23 October 2001	Siatou, E
Place of search	Date of completion of the search	Examiner							
BERLIN	23 October 2001	Siatou, E							



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 01 11 3662

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	<p>KO F-N ET AL: "YC-1, A NOVEL ACTIVATOR OF PLATELET GUANYLATE CYCLASE" BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 84, no. 12, 15 December 1994 (1994-12-15), pages 4226-4233, XP000878904 ISSN: 0006-4971 * abstract *</p> <p>-----</p>	1,2,4,5, 17-19, 21-24	
TECHNICAL FIELDS SEARCHED (Int.Cl.7)			
<p>The present search report has been drawn up for all claims</p>			
Place of search	Date of completion of the search	Examiner	
BERLIN	23 October 2001	Siatou, E	
<b>CATEGORY OF CITED DOCUMENTS</b> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 11 3662

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

23-10-2001

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 667345	A	16-08-1995	JP	2928079 B2	28-07-1999
			JP	7224057 A	22-08-1995
			US	5574168 A	12-11-1996
			DE	69512444 D1	04-11-1999
			DE	69512444 T2	09-03-2000
			EP	0667345 A1	16-08-1995
<hr/>					
WO 9816223	A	23-04-1998	DE	19642255 A1	16-04-1998
			AU	733967 B2	31-05-2001
			AU	5049498 A	11-05-1998
			BR	9712304 A	31-08-1999
			CZ	9901292 A3	14-07-1999
			EE	9900156 A	15-12-1999
			WO	9816223 A1	23-04-1998
			EP	0932403 A1	04-08-1999
			HU	9903885 A2	28-11-2000
			JP	2001502318 T	20-02-2001
			NO	991685 A	09-04-1999
			PL	332719 A1	11-10-1999
			SK	46599 A3	14-02-2000
			TR	9900782 T2	21-07-1999
			US	6180656 B1	30-01-2001
<hr/>					

EPO FORM PB459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82